IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, October 2025
Impact Factor: 7.67

A Review On Minoxidil a Potent Hair growth Agent

Komal kale[1], Shruti Tanpure[2], Prajakta Bhujbal[3], Sarthak Narode[4], Jayashri Kasar[5]
Students, Department of Pharmacy[1,2,3,4]
Guide, Department of Pharmacy[5]
Mrs. Saraswati Wani College of Pharmacy, Ganegaon, Maharashtra
Affiliated to Dr Babasaheb Aambedkar Technological University, Lonore, Raigad

Abstract: *Minoxidil was initially prescribed as an antihypertensive drug, and after its frequent side effect, hypertrichosis, was identified, a topical version for hair growth promotion was created. The standard treatment for androgenetic alopecia is currently topical minoxidil, which is also used off-label to treat other types of hair loss. Even with its extensive use, minoxidil's precise mode of action is still unclear. The purpose of this page is to evaluate and update the most recent data regarding topical minoxidil's pharmacology, mechanism of action, clinical effectiveness, and side effects.*

Keywords: alopecia, beard, eyebrow, hair growth, treatment

I. INTRODUCTION

In the 1970s, minoxidil was initially made available orally to treat severe and resistant hypertension. One As a result of doctors' observations of balding patients' generalized hypertrichosis and hair regeneration, a topical minoxidil formulation was created to treat androgenetic alopecia (AGA), initially in males and later in women. In 1986, the 2% minoxidil solution was introduced to the market, then in 1993, the 5% solution. 2. Even after more than three decades of widespread use, the exact mechanism by which minoxidil promotes hair growth is still unknown. Reviewing and updating important clinical data on topical minoxidil, such as its pharmacology, mode of action, clinical effectiveness, and side effects, was our goal.

History of Minoxidil:

Minoxidil was first introduced in the early 1970s as an oral drug for severe hypertension due to its strong vasodilatory properties . Hypertrichosis (abnormal hair growth) was observed in patients taking oral minoxidil, leading researchers to explore its potential in hair disorders. In 1988, the U.S. Food and Drug Administration (FDA) approved topical 2% minoxidil solution for androgenetic alopecia in men, followed by 5% solutions and foam formulations. The cosmetic industry has shifted towards developing alcohol-free, serum-based formulations of minoxidil to overcome issues of irritation and poor acceptability seen in traditional solutions.

Mechanism of Minoxidil:

1 . Vasodilation and Increased Blood Flow - Minoxidil acts as a potassium channel opener, causing vasodilation. This enhances blood circulation in the scalp, ensuring more oxygen, nutrients, and growth factors reach the hair follicles.

2 . Prolongation of Anagen Phase - Hair grows in cycles: anagen (growth), catagen (transition), and telogen (resting). Minoxidil prolongs the anagen phase while shortening the telogen phase, leading to thicker and denser hair.

3 . Stimulation of Dermal Papilla Cells - Minoxidil activates dermal papilla cells (DPCs), which play a critical role in regulating hair follicle size and cycling.

4 . VEGF Upregulation - Vascular Endothelial Growth Factor (VEGF) levels increase in minoxidil-treated follicles, leading to angiogenesis and larger, healthier follicles.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, October 2025
Impact Factor: 7.67

5 . Anti-Apoptotic Effects - Prevents programmed cell death of follicular keratinocytes, ensuring continued follicle survival and activity.



Fig . Mechanism of Minoxidil in hair growth

Biological activity of Minoxidil:

Minoxidil has been used for decades in hair loss management, where it stimulates follicular cells, promotes hair growth, and reduces shedding. Discontinuation usually results in relapse within 12–24 weeks. Experimental studies showed that minoxidil shortens the telogen phase, increases DNA synthesis in anagen bulbs, and activates secondary germ cells, thereby accelerating the shift to the anagen phase.

Clinical trials in androgenetic alopecia confirmed that 2% and 5% minoxidil solutions significantly improve hair density, with the 5% formulation being more effective. Minoxidil also prolongs the anagen interval through β-catenin activation, increasing follicle size and stimulating proliferation of dermal papilla cells.

In addition, vascular effects have been noted, including increased perifollicular angiogenesis via VEGF upregulation and induction of hypoxia-inducible factor-1α. Minoxidil also modulates prostaglandin pathways by enhancing PGE2 production and receptor expression, which supports continuous follicular activity and maintenance of the anagen phase.

Clinical Applications of Serum-Based Minoxidil

1. Treats androgenetic alopecia in men and women, improving hair density and thickness.
2. 5% serum is more effective in men; 2% is preferred for women.
3. Can be used off-label for alopecia areata to stimulate patchy hair regrowth.
4. Strengthens thinning hair and reduces breakage by activating dermal papilla cells.
5. Improves hair quality, texture, and overall scalp health.
6. Supports hair recovery after chemical treatments like coloring, bleaching, or straightening.
7. Prevents early hair thinning by maintaining follicle activity and prolonging the anagen phase.
8. Serum formulation is non-greasy, lightweight, and fast-absorbing, making it easy to apply.
9. Provides better penetration and reduced scalp irritation, enhancing compliance and results .

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, October 2025
Impact Factor: 7.67

Advantages of Serum-Based Minoxidil

1. Stimulates hair growth and reduces hair loss.
2. Non-greasy, lightweight, and easy to apply.
3. Better penetration into the scalp for effective results.
4. Reduces scalp irritation compared to lotions or foams.
5. Strengthens hair, reduces breakage, and improves shine.
6. Can be applied directly to affected areas for targeted action.
7. Encourages regular use due to pleasant texture and cosmetic appeal.

Limitations of Hair Serum

1 . Temporary Effects – results last only with regular use; discontinuation may reduce benefits.
2 . Cost – some high-quality serums can be expensive.
3 . Potential Build-Up – silicones or heavy ingredients may accumulate on hair over time.
4 . Not a Complete Cure – may not fully treat severe hair loss or scalp disorders.
5 . Allergic Reactions – some ingredients may cause irritation or sensitivity in certain users.
6 . Overuse Issues – excessive application can make hair greasy or weigh it down.
7 . Limited Penetration – some nutrients or actives may not reach deep follicle layers.

Properties of Hair Serum :

1. Featherlight andNon-Greasy – fluently spreads and absorbs without leaving residue.
2. Smooth Texture – provides silkiness and soft sense to hair.
3. Defensive Film conformation – fleeces hair shaft to help damage from heat, chemicals, and terrain.
4. Moisturizing – helps retain hair humidity and prevents blankness. 5. Frizz Control – reduces tangling and manages flyaways.
6. nutritional – delivers vitamins, nutrients, or actives to hair and crown.
7. Shine improvement – makes hair lustrous and healthy- looking.
8. Easy Application – generally leave- on and accessible for diurnal use.

II. CONCLUSION

Hair serums, whether synthetic or herbal- grounded, are effective topical phrasings for promoting hair growth, perfecting hair texture, and guarding hair from damage. Synthetic actives like minoxidil stimulate follicular cells, protract the anagen phase, and enhance crown blood inflow, making them largely effective for hair loss operation. Herbal constituents similar as neem and curry leaves give antimicrobial, antioxidant, and nutritional benefits, reducing hair fall, precluding dandruff, and strengthening hair. Serum phrasings are featherlight,non-greasy, and easy to apply, icing better compliance and targeted action. Still, regular use is essential to maintain results, and some phrasings may beget crown vexation or make- up if overused. Overall, combining synthetic and herbal actives in hair serums offers a promising approach for healthy, strong, and candescent hair, addressing both remedial and ornamental requirements.

REFERENCES

[1]. https://en.m.wikipedia.org/wiki/Minoxidil
[2]. https://www.drugs.com/minoxidil.html
[3]. https://go.drugbank.com/drugs/DB00350
[4]. *Campese VM. Minoxidil: a review of its pharmacological properties and therapeutic use. Drugs. 1981;22(4):257–278. doi: 10.2165/00003495-198122040-00001*
[5]. Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S. Minoxidil use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012;6(2):130–136.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, October 2025
Impact Factor: 7.67

[6]. Minoxidil: Mechanisms of Action on Hair Growth Messenger AG. British Journal of Dermatology. 2004.

[7]. Purnak T, Senel E, Sahin C. Liquid formulation of minoxidil versus its foam formulation. *Indian J Dermatol*. 2011;56(4):462. doi: 10.4103/0019-5154.84714

[8]. Shorter K, Farjo NP, Picksley SM, Randall VA. Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. Faseb J. 2008;22(6):1725–1736. Doi: 10.1096/fj.07-099424

[9]. Buhl AE, Waldon DJ, Kawabe TT, Holland JM. Minoxidil stimulates mouse vibrissae follicles in organ culture. J Invest Dermatol. 1989;92(3):315–320.

[10]. Anderson RJ, Kudlacek PE, Clemens DL. Sulfation of minoxidil by multiple human cytosolic sulfotransferases. Chem Biol Interact. 1998;109(1–3):53–67.

[11]. Cohen RL, Alves MEAF, Weiss VC, West DP, Chambers DA. Direct goods of minoxidil on epidermal cells in culture. J Invest Dermatol 1984; 8290- 3.

[12]. Baden HP, Kubilus J. Effect of minoxidil on dressed keratinocytes. J Invest Dermatol 1983; 81558- 60.

[13]. Tata S, Weiner N, Flynn G. Relative influence of ethanol and propylene glycol cosolvents on deposit of minoxidil into the skin. J Pharmacol Sci 1994; 831508- 10.

[14]. Savin RC, Atton AV. Minoxidil update on its clinical part. Dermatologic remedy 1993; 1155- 64.

[15]. Ferri JJ, Shepard JH, Szpunar GJ. Relationship between contact time of applied cure and percutaneous immersion of minoxidil from topical result. J Pharm Sci 1990; 79483- 6.

[16]. Messenger AG, Rundegren J. Minoxidil mechanisms of action on hair growth. British Journal of Dermatology 2004; 150186 – 194.

[17]. Mori O, Uno H. The effect of topical minoxidil on hair follicular cycles of rats. J Dermatol 1990;

[18]. Uno H, Cappas A, Brigham P. Action of topical minoxidil in the bald refuse- tagged macaque. J Am Acad Dermatol 1987; 16657 – 68.

[19]. Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia, after operation of 5 and 2 topical minoxidil, placebo, or no treatment. J Am Acad Dermatol 1999; 41717 – 21.

[20]. Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, Trancik RJ. A randomized clinical trial of 5 topical minoxidil versus 2 topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002; 47377 – 85.